Volume 8; Issue 10

Molecular Cancer Therapeutics

Volume 8; Issue 10

1

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone

Ottewell, P. D., Woodward, J. K., Lefley, D. V., Evans, C. A., Coleman, R. E., Holen, I.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 573 KB

english, 2009

2

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

Mumenthaler, S. M., Ng, P. Y.B., Hodge, A., Bearss, D., Berk, G., Kanekal, S., Redkar, S., Taverna, P., Agus, D. B., Jain, A.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 703 KB

english, 2009

3

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F., Chong, W. Y., Hummersone, M., Rigoreau, L., Menear, K. A., O'Connor, M. J., Povirk, L. F., van Meter, T., Vale

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 378 KB

english, 2009

4

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

Schmidt, M. M., Wittrup, K. D.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 466 KB

english, 2009

5

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., Friedman, H. S., Bigner, D. D.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 152 KB

english, 2009

6

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA

Vispe, S., DeVries, L., Creancier, L., Besse, J., Breand, S., Hobson, D. J., Svejstrup, J. Q., Annereau, J.-P., Cussac, D., Dumontet, C., Guilbaud, N., Barret, J.-M., Bailly, C.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 899 KB

english, 2009

7

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

Zheng, B., Fuji, R. N., Elkins, K., Yu, S.-F., Fuh, F. K., Chuh, J., Tan, C., Hongo, J.-A., Raab, H., Kozak, K. R., Williams, M., McDorman, E., Eaton, D., Ebens, A., Polson, A. G.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 1012 KB

english, 2009

8

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

Kuznetsov, G., TenDyke, K., Towle, M. J., Cheng, H., Liu, J., Marsh, J. P., Schiller, S. E.R., Spyvee, M. R., Yang, H., Seletsky, B. M., Shaffer, C. J., Marceau, V., Yao, Y., Suh, E. M., Campagna, S.,

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 512 KB

english, 2009

9

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells

Yamada, T., Mehta, R. R., Lekmine, F., Christov, K., King, M. L., Majumdar, D., Shilkaitis, A., Green, A., Bratescu, L., Beattie, C. W., Das Gupta, T. K.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 996 KB

english, 2009

10

Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., Diamond, P., Zannettino, A. C.W., Findlay, D. M., Evdokiou, A.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 1.10 MB

english, 2009

11

Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1 activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect

Lee, W. H., Kim, Y. W., Choi, J. H., Brooks, S. C., Lee, M.-O., Kim, S. G.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 1.02 MB

english, 2009

12

Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells

Hu, H., Chai, Y., Wang, L., Zhang, J., Lee, H. J., Kim, S.-H., Lu, J.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 961 KB

english, 2009

13

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

Schneiders, U. M., Schyschka, L., Rudy, A., Vollmar, A. M.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 1.08 MB

english, 2009

14

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

Wilson, W. R., Stribbling, S. M., Pruijn, F. B., Syddall, S. P., Patterson, A. V., Liyanage, H.D. S., Smith, E., Botting, K. J., Tercel, M.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 785 KB

english, 2009

15

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2

To, K. K.W., Robey, R. W., Knutsen, T., Zhan, Z., Ried, T., Bates, S. E.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 649 KB

english, 2009

16

Correction: SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor- B activation, c-Fos/c-Jun expression, and cellular apoptosis

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 92 KB

english, 2009

17

Quantification of endothelial cell-targeted anti-Bcl-2 therapy and its suppression of tumor growth and vascularization

Jain, H. V., Nor, J. E., Jackson, T. L.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 694 KB

english, 2009

18

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

Gao, C.-F., Xie, Q., Zhang, Y.-W., Su, Y., Zhao, P., Cao, B., Furge, K., Sun, J., Rex, K., Osgood, T., Coxon, A., Burgess, T. L., Vande Woude, G. F.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 329 KB

english, 2009

19

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

Daenen, L. G., Shaked, Y., Man, S., Xu, P., Voest, E. E., Hoffman, R. M., Chaplin, D. J., Kerbel, R. S.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 491 KB

english, 2009

20

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Sabbatini, P., Korenchuk, S., Rowand, J. L., Groy, A., Liu, Q., Leperi, D., Atkins, C., Dumble, M., Yang, J., Anderson, K., Kruger, R. G., Gontarek, R. R., Maksimchuk, K. R., Suravajjala, S., Lapierre

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 602 KB

english, 2009

21

Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors

Konsoula, Z., Cao, H., Velena, A., Jung, M.

Journal:

Molecular Cancer Therapeutics

Year:

2009

Language:

english

File:

PDF, 525 KB

english, 2009